• 13,717 fully anonymized subject records
• 44 Phase II/III clinical trials comprising placebo and active treatment cohorts
• Rich multidimensional datasets, including demographics, lab tests, medical and family history, and clinical outcomes
• 18+ million longitudinal data points

The popularity of the project is illustrated by the following statistics:

• Registed users: 3343
• Countries: 87
• Downloads: 24270

We thank everyone who has contributed to the creation of PRO-ACT including the companies, the researchers, and most of all the ALS patients, past and present, around the world, to whom the PRO-ACT initiative is dedicated:

• Alexion Pharmaceuticals, Inc.
• ALS Therapy Alliance
• Amylyx Pharmaceuticals, Inc.
• Apellis Pharmaceuticals, Inc.
• Cytokinetics, Inc.
• Knopp Biosciences
• Neuraltus Pharmaceuticals, Inc.
• Neurological Clinical Research Institute, Massachusetts General Hospital
• Northeast ALS Consortium
• Novartis
• Orion Corporation
• Prize4Life Israel
• PTC Therapeutics, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Teva Pharmaceutical Industries, Ltd.
• The ALS Association
• The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital
• University Medical Center Utrecht

Click here to read our Open-Science Policy Statement